Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 Approval of BLA would unlock a $31 Million milestone payment from Pierre Fabre Laboratories Nine-

